CONNECT WITH US
Tech

Tech

How One Company Brings AI Into the Lab to Find New Peptides for Health

CNET - Tech logo

Published on

Add as a preferred source on Google
How One Company Brings AI Into the Lab to Find New Peptides for Health

If asked what the two major buzzwords of 2026 were, I’d immediately say artificial intelligence and peptides. One Irish company is bringing both of these together.

It had been since high school that I’d donned a white coat and looked at cells under a microscope. But at Nuritas’ labs in the heart of Dublin, Ireland, I did just that to learn more about the intersection of AI and peptides.

Nuritas, a Dublin-based biotechnology company, brings together AI models, clinically proven peptide ingredients and cutting-edge science to accelerate the discovery of peptides that can be used for products intended to boost human health. Founded in 2014 by Nora Khaldi, a mathematician with a doctoral degree in molecular evolution and bioinformatics, the Nuritas team consists of scientists, AI specialists and industry experts to create health products for things like skincare, nutrition, muscle health, better sleep and aging.

Last month, I toured Nuritas, a beautiful converted bank that overlooks the city with views of Mansion House, the oldest Georgian house in Ireland and the Guinness Storehouse at St. James Gate. I spoke with Khaldi and two of the team’s top scientists to learn more about their patented products, peptide discovery and how AI systems fit into the process. 

Peptides have been all the rage in the health sector, driven by the popularity of GLP-1 medications like Ozempic and Wegovy. These drugs use synthetic peptides inspired by those naturally found in the saliva and venom of the Gila monster, a lizard native to parts of North America, for weight management, cardiovascular risk reduction and treatment of Type 2 diabetes.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.